A team of international astronomers, including a University of Michigan doctoral student, were the first to publish the ...

The "Momentum 3" study found that none of the 152 HeartMate 3 patients wound up with pump thrombosis, while 14 of the HeartMate II patients had it after six months.

Methods: This was a post hoc analysis of the MOMENTUM 3 pivotal trial [HM3 vs HeartMate II (HMII) LVAD therapy] and the continued access protocol (single-arm HM3 LVAD therapy). A total of 2,200 ...

The MOMENTUM 3 trial studied more than 1000 patients and for the first time in a clinical trial setting found that people with advanced heart failure who received the HeartMate 3 heart pump lived ...

(RTTNews) - Abbott (ABT) said the data from the MOMENTUM 3 trial showed its HeartMate 3 heart pump extended survival of advanced heart failure patients by at least five years. Results of the five ...

The newly released data comes from the medtech’s Momentum 3 trial, which tracked outcomes for five years after the HeartMate 3 was put in place and compared those to the results of both heart ...

The MOMENTUM 3 study data compared Abbott's HeartMate 3 pump to its HeartMate II pump in treating people with advanced (New York Heart Association Class IIIB or IV) heart failure.

The MOMENTUM 3 trial studied more than 1000 patients and for the first time in a clinical trial setting found that people with advanced heart failure who received the HeartMate 3 heart pump lived ...

Abbott (NYSE: ABT) today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least five years, providing a clear ...

Abbott shared the results from its MOMENTUM-3 randomized trial during a late-breaking presentation at the European Society of Cardiology Congress in Barcelona, Spain. More than 1,000 patients were ...